Akebia Therapeutics (AKBA) and U.S. Renal Care have entered into a comprehensive multi-year agreement for the commercial supply of products to all USRC dialysis facilities. This contract authorizes physicians at USRC locations to prescribe Vafseo to dialysis patients starting from its anticipated availability in January 2025.
Vafseo received approval from the FDA in March 2024 for the treatment of anemia associated with chronic kidney disease in adults who have been undergoing dialysis for a minimum of three months. Akebia anticipates obtaining a Transitional Drug Add-on Payment Adjustment designation for Vafseo by January 2025.